GlassScriptPhysician profile
Brian Lee Mcclune
NPI 1649296880
$8,358.76
in general payments reported to CMS, 2019-2025
14 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.30 · 2021: $36.45 · 2022: $56.27 · 2023: $1,609 · 2024: $4,805 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,675 · Travel and Lodging: $3,020 · Food and Beverage: $1,488 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,675.00 |
| Travel and Lodging | $3,019.74 |
| Food and Beverage | $1,487.75 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| National Marrow Donor Program | $3,997.58 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $3,025.00 | 2024 | Tecvayli |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Kite Pharma, INC. | $164.05 | 2019-2024 | Yescarta |
| Novartis Pharmaceuticals Corporation | $146.14 | 2024 | |
| Incyte Corporation | $124.72 | 2025 | Niktimvo |
| Genzyme Corporation | $92.47 | 2023 | |
| Pfizer INC. | $56.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Janssen Biotech, INC. | $36.45 | 2021 | |
| Menarini Silicon Biosystems, INC. | $22.83 | 2023 | Cellsearch |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcclune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.